Dan McHugh

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands.

Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

New York Ventures (New York State Innovation) is a venture capital subsidiary of Empire State Development Corp. The firm is headquartered in New York.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Bodyport, Inc. manufactures sensor fitted weighing scales. It offers scale that measures weight like others do, but also measures blood pressure, heart rate, heart rate variability, and arterial stiffness through a user's feet. The company was founded by Corey Centen and Sarah Smith and is headquartered in San Francisco, CA.

Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA.

Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

1200 Pharma LLC engages in the provision of pre-clinical drug discovery and clinical approval timelines. The company is headquartered in Pasadena, CA.

Accelerate Long Island/venture capital/ (Accelerate Long Island (Venture Capital)) is a venture capital subsidiary of Accelerate Long Island, Inc founded in 2016. The firm is headquartered in Melville, New York.

Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA.

Pinpoint Therapeutics, Inc. provides cancer treatment. The firm specializes in developing novel treatments for cancer. The company was founded by Jeffrey Winkler and Ravi Amaravadi in 2018 and is headquartered in Philadelphia, PA.

Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA.

Leukovet develops peptide-based cancer therapeutics for the treatment of canine lymphoma, leukemia, and other immunological diseases. The company is based in New York, NY. The company was founded in 2019. The CEO is Sonia Gulati.

Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands.

TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation.